Search results
Filter
12 results
Sort by:
'Middle-England diocese, Middle-England Catholicism' : the development of the Roman Catholic Diocese of Nottingham 1850-1915
The thesis aims to chart the development of the Diocese of Nottingham from 1850 to 1915, and through a comparison with the historiography of the period, to show how far it correlates with the accepted norms of nineteenth and early twentieth century Catholic development. Methodologically, the thesis aims to pioneer an in-depth integrated study on the development of the Diocese of Nottingham from 1850 to 1915, a largely unstudied area as far as Catholics and Catholicism is concerned. The period studied commences with the Restoration of the Hierarchy, (1850), and terminates with the resignation of Bishop Brindle in 1915. There is a unity in the period chosen as it encompasses the Episcopacies of one Diocesan Administrator, Bishop William Bernard Ullathorne (1850-1, who was concurrently Bishop of Birmingham), and Bishop Joseph William Hendren, (1851-3), Bishop Richard Roskell (1853-74), Bishop Edward Bagshawe (1874-1901), and Bishop Robert Brindle (1901-15). While the thesis addresses the way the Bishops tackled the problems they faced on taking up their appointments, as well as the ways in which they dealt with the demands placed upon them by Westminster, the emphasis is on the broader Catholic community and the way it evolved. This is dealt with through a wide-ranging analysis which locates local developments within a national framework. While each chapter has a dominant focus for organisational reasons, the thesis aims is to show how matters inter-related, and subsequently affected the Diocese's developmental path. The overall outline of the Diocese's historical background between 1850 and 1915, is described through a study of the characteristics, aims and methods used by Bishop Ullathorne, and the Bishops of Nottingham, in their attempts to turn the Diocese of Nottingham from a 2 concept on paper in 1850, to being an important part of the cultural, social and religious landscape of the East Midlands by 1915. Succeeding chapters deal with ultramontanism and how it was uniquely interpreted locally, defining who comprised the local Catholic community, the evolution of a Diocesan political ethos, education, and anti-Catholicism: the latter may be seen as perhaps the example par excellence of the need for integrated studies. The primary sources used in this thesis bring new perspectives to the study of nineteenth century Catholicism, and their use greatly extends our knowledge and understanding of the period. This is especially true as they have not been applied before to an understanding of the Nottingham Diocese. Use has been made of around 80 newspapers (daily, twice weekly and weekly) and monthly magazines, both Catholic and Protestant, published across the Diocese, as well as national publications. In several cases, as in Nottingham and Leicester, their attitudes varied from being anti- to pro- Catholic, which meant a greater degree of balance in the understanding of events. Use was also made of newly available papers from the De Lisle, Gainsborough, and Howard families that have not been used before. Other material was personally collected from the descendants of nineteenth century families. In addition to papers from the Orders' Archives, the Westminster and Birmingham Arch-Diocesan Archives, the Vatican and other Diocesan Archives have been consulted, such as those at Northampton, Salford and Leeds. The Nottingham Archives provided material that has not been used before, including the extant papers of Bishops Ullathorne, Hendren, Roskell, Bagshawe, Brindle, and Dunn. Access was given to extracts from the Chapter Minutes and newly deposited material from priests who were active in the period. As well as explaining how the Nottingham Diocese developed between 1850 and 1915, the thesis deals with the differences noted locally between `Catholicism' and 3 `Catholic'. Attempts are made to explain the dichotomy noted; namely that while `Catholicism' entailed hatred and led to anti-Catholicism, individual `Catholics' were frequently admired and respected. The thesis will make an important contribution to our knowledge in a number of ways. Fundamentally, it is the only macro-diocesan study of its type. The newly available content will provide an increased data base for studies of nineteenth-century Catholicism. By synthesising the information, localised trends have been established which are compared to, or used to correct, generalisations portrayed in the historiography of secondary literature that currently exists. The newly available information can also be used to test some of the hypotheses used regarding Catholics. The structure of the thesis will hopefully lay down a model for further Diocesan studies.
BASE
Money transmission, today and tomorrow: the Ernest Sykes memorial lectures delivered in the Library of the Institute of Bankers, November 1974
In: Ernest Sykes memorial lectures 1974
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse
Background: Simple, affordable diagnostic tools are essential to facilitate global hepatitis C virus (HCV) elimination efforts. Objectives: This study evaluated the clinical performance of core antigen (HCVcAg) assay from plasma samples to monitor HCV treatment efficacy and HCV viral recurrence. Study design: Plasma samples from a study of response-guided pegylated-interferon/ribavirin therapy for people who inject drugs with chronic HCV genotype 2/3 infection were assessed for HCV RNA (AmpliPrep/COBAS Taqman assay, Roche) and HCVcAg (ARCHITECT HCV Ag, Abbott Diagnostics) during and after therapy. The sensitivity and specificity of the HCVcAg assay was compared to the HCV RNA assay (gold standard). Results: A total of 335 samples from 92 enrolled participants were assessed (mean 4 time-points per participant). At baseline, end of treatment response (ETR) and sustained virological response (SVR) visits, the sensitivity of the HCVcAg assay with quantifiable HCV RNA threshold was 94% (95% CI: 88%, 98%), 56% (21%, 86%) and 100%, respectively. The specificity was between 98 to 100% for all time-points assessed. HCVcAg accurately detected all six participants with viral recurrence, demonstrating 100% sensitivity and specificity. One participant with detectable (non-quantifiable) HCV RNA and non-reactive HCVcAg at SVR12 subsequently cleared HCV RNA at SVR24. Conclusions: HCVcAg demonstrated high sensitivity and specificity for detection of pre-treatment and post-treatment viraemia. This study indicates that confirmation of active HCV infection, including recurrent viraemia, by HCVcAg is possible. Reduced on-treatment sensitivity of HCVcAg may be a clinical advantage given the moves toward simplification of monitoring schedules. ; This study was funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales. The opinions expressed in this paper are those of the authors and do not necessarily represent that of Merck Sharp and Dohme. Support from Abbott Diagnostics for the supply of reagents is gratefully acknowledged. GD is supported by a National Health and Medical Research Council Practitioner Research Fellowships. JG is supported by a National Health and Medical Research Council Career Development Fellowship. BH is supported by a National Health and Medical Research Council Early Career Fellowship. The ARCHITECT HCV Ag kits for this study were kindly provided by Abbott.
BASE
Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK
This report contains new and follow-up metric data relating to the eight main recommendations of the Lancet Standing Commission on Liver Disease in the UK, which aim to reduce the unacceptable harmful consequences of excess alcohol consumption, obesity, and viral hepatitis. For alcohol, we provide data on alcohol dependence, damage to families, and the documented increase in alcohol consumption since removal of the above-inflation alcohol duty escalator. Alcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working life lost. The rising prevalence of overweight and obesity, affecting more than 60% of adults in the UK, is leading to an increasing liver disease burden. Favourable responses by industry to the UK Government's soft drinks industry levy have been seen, but the government cannot continue to ignore the number of adults being affected by diabetes, hypertension, and liver disease. New direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortality and the number of patients requiring liver transplantation, but more screening campaigns are needed for identification of infected people in high-risk migrant communities, prisons, and addiction centres. Provision of care continues to be worst in regions with the greatest socioeconomic deprivation, and deficiencies exist in training programmes in hepatology for specialist registrars. Firm guidance is needed for primary care on the use of liver blood tests in detection of early disease and the need for specialist referral. This report also brings together all the evidence on costs to the National Health Service and wider society, in addition to the loss of tax revenue, with alcohol misuse in England and Wales costing £21 billion a year (possibly up to £52 billion) and obesity costing £27 billion a year (treasury estimates are as high as £46 billion). Voluntary restraints by the food and drinks industry have had little effect on disease burden, and concerted regulatory and fiscal action by the UK Government is essential if the scale of the medical problem, with an estimated 63 000 preventable deaths over the next 5 years, is to be addressed.
BASE
Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK
In: Williams , R , Aithal , G , Alexander , G J , Allison , M , Armstrong , I , Aspinall , R , Baker , A , Batterham , R , Brown , K , Burton , R , Cramp , M E , Day , N , Dhawan , A , Drummond , C , Ferguson , J , Foster , G , Gilmore , I , Greenberg , J , Henn , C , Jarvis , H , Kelly , D , Mathews , M , McCloud , A , MacGilchrist , A , McKee , M , Moriarty , K , Morling , J , Newsome , P , Rice , P , Roberts , S , Rutter , H , Samyn , M , Severi , K , Sheron , N , Thorburn , D , Verne , J , Vohra , J , Williams , J & Yeoman , A 2020 , ' Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK ' , The Lancet , vol. 395 , no. 10219 , pp. 226-239 . https://doi.org/10.1016/S0140-6736(19)32908-3
This final report of the Lancet Commission into liver disease in the UK stresses the continuing increase in burden of liver disease from excess alcohol consumption and obesity, with high levels of hospital admissions which are worsening in deprived areas. Only with comprehensive food and alcohol strategies based on fiscal and regulatory measures (including a minimum unit price for alcohol, the alcohol duty escalator, and an extension of the sugar levy on food content) can the disease burden be curtailed. Following introduction of minimum unit pricing in Scotland, alcohol sales fell by 3%, with the greatest effect on heavy drinkers of low-cost alcohol products. We also discuss the major contribution of obesity and alcohol to the ten most common cancers as well as measures outlined by the departing Chief Medical Officer to combat rising levels of obesity—the highest of any country in the west. Mortality of severely ill patients with liver disease in district general hospitals is unacceptably high, indicating the need to develop a masterplan for improving hospital care. We propose a plan based around specialist hospital centres that are linked to district general hospitals by operational delivery networks. This plan has received strong backing from the British Association for Study of the Liver and British Society of Gastroenterology, but is held up at NHS England. The value of so-called day-case care bundles to reduce high hospital readmission rates with greater care in the community is described, along with examples of locally derived schemes for the early detection of disease and, in particular, schemes to allow general practitioners to refer patients directly for elastography assessment. New funding arrangements for general practitioners will be required if these proposals are to be taken up more widely around the country. Understanding of the harm to health from lifestyle causes among the general population is low, with a poor knowledge of alcohol consumption and dietary guidelines. The Lancet Commission has serious doubts about whether the initiatives described in the Prevention Green Paper, with the onus placed on the individual based on the use of information technology and the latest in behavioural science, will be effective. We call for greater coordination between official and non-official bodies that have highlighted the unacceptable disease burden from liver disease in England in order to present a single, strong voice to the higher echelons of government.
BASE
Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK
This report presents further evidence on the escalating alcohol consumption in the UK and the burden of liver disease associated with this major risk factor, as well as the effects on hospital and primary care. We reiterate the need for fiscal regulation by the UK Government if overall alcohol consumption is to be reduced sufficiently to improve health outcomes. We also draw attention to the effects of drastic cuts in public services for alcohol treatment, the repeated failures of voluntary agreements with the drinks industry, and the influence of the industry through its lobbying activities. We continue to press for reintroduction of the alcohol duty escalator, which was highly effective during the 5 years it was in place, and the introduction of minimum unit pricing in England, targeted at the heaviest drinkers. Results from the introduction of minimum unit pricing in Scotland, with results from Wales to follow, are likely to seriously expose the weakness of England's position. The increasing prevalence of obesity-related liver disease, the rising number of people diagnosed with type 2 diabetes and its complications, and increasing number of cases of end-stage liver disease and primary liver cancers from non-alcoholic fatty liver disease make apparent the need for an obesity strategy for adults. We also discuss the important effects of obesity and alcohol on disease progression, and the increased risk of the ten most common cancers (including breast and colon cancers). A new in-depth analysis of the UK National Health Service (NHS) and total societal costs shows the extraordinarily large expenditures that could be saved or redeployed elsewhere in the NHS. Excellent results have been reported for new antiviral drugs for hepatitis C virus infection, making elimination of chronic infection a real possibility ahead of the WHO 2030 target. However, the extent of unidentified cases remains a problem, and will also apply when new curative drugs for hepatitis B virus become available. We also describe efforts to ...
BASE
Gathering momentum for the way ahead:fifth report of the Lancet Standing Commission on Liver Disease in the UK
In: Williams , R , Alexander , G , Aspinall , R , Batterham , R , Bhala , N , Bosanquet , N , Severi , K , Burton , A , Burton , R , Cramp , M E , Day , N , Dhawan , A , Dillon , J , Drummond , C , Dyson , J , Ferguson , J , Foster , G R , Gilmore , I , Greenberg , J , Henn , C , Hudson , M , Jarvis , H , Kelly , D , Mann , J , McDougall , N , McKee , M , Moriarty , K , Morling , J , Newsome , P , O'Grady , J , Rolfe , L , Rice , P , Rutter , H , Sheron , N , Thorburn , D , Verne , J , Vohra , J , Wass , J & Yeoman , A 2018 , ' Gathering momentum for the way ahead : fifth report of the Lancet Standing Commission on Liver Disease in the UK ' , The Lancet , vol. 392 , no. 10162 , pp. 2398-2412 . https://doi.org/10.1016/S0140-6736(18)32561-3
This report presents further evidence on the escalating alcohol consumption in the UK and the burden of liver disease associated with this major risk factor, as well as the effects on hospital and primary care. We reiterate the need for fiscal regulation by the UK Government if overall alcohol consumption is to be reduced sufficiently to improve health outcomes. We also draw attention to the effects of drastic cuts in public services for alcohol treatment, the repeated failures of voluntary agreements with the drinks industry, and the influence of the industry through its lobbying activities. We continue to press for reintroduction of the alcohol duty escalator, which was highly effective during the 5 years it was in place, and the introduction of minimum unit pricing in England, targeted at the heaviest drinkers. Results from the introduction of minimum unit pricing in Scotland, with results from Wales to follow, are likely to seriously expose the weakness of England's position. The increasing prevalence of obesity-related liver disease, the rising number of people diagnosed with type 2 diabetes and its complications, and increasing number of cases of end-stage liver disease and primary liver cancers from non-alcoholic fatty liver disease make apparent the need for an obesity strategy for adults. We also discuss the important effects of obesity and alcohol on disease progression, and the increased risk of the ten most common cancers (including breast and colon cancers). A new in-depth analysis of the UK National Health Service (NHS) and total societal costs shows the extraordinarily large expenditures that could be saved or redeployed elsewhere in the NHS. Excellent results have been reported for new antiviral drugs for hepatitis C virus infection, making elimination of chronic infection a real possibility ahead of the WHO 2030 target. However, the extent of unidentified cases remains a problem, and will also apply when new curative drugs for hepatitis B virus become available. We also describe efforts to improve standards of hospital care for liver disease with better understanding of current service deficiencies and a new accreditation process for hospitals providing liver services. New commissioning arrangements for primary and community care represent progress, in terms of effective screening of high-risk subjects and the early detection of liver disease.
BASE
Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK
This report presents further evidence on the escalating alcohol consumption in the UK and the burden of liver disease associated with this major risk factor, as well as the effects on hospital and primary care. We reiterate the need for fiscal regulation by the UK Government if overall alcohol consumption is to be reduced sufficiently to improve health outcomes. We also draw attention to the effects of drastic cuts in public services for alcohol treatment, the repeated failures of voluntary agreements with the drinks industry, and the influence of the industry through its lobbying activities. We continue to press for reintroduction of the alcohol duty escalator, which was highly effective during the 5 years it was in place, and the introduction of minimum unit pricing in England, targeted at the heaviest drinkers. Results from the introduction of minimum unit pricing in Scotland, with results from Wales to follow, are likely to seriously expose the weakness of England's position. The increasing prevalence of obesity-related liver disease, the rising number of people diagnosed with type 2 diabetes and its complications, and increasing number of cases of end-stage liver disease and primary liver cancers from non-alcoholic fatty liver disease make apparent the need for an obesity strategy for adults. We also discuss the important effects of obesity and alcohol on disease progression, and the increased risk of the ten most common cancers (including breast and colon cancers). A new in-depth analysis of the UK National Health Service (NHS) and total societal costs shows the extraordinarily large expenditures that could be saved or redeployed elsewhere in the NHS. Excellent results have been reported for new antiviral drugs for hepatitis C virus infection, making elimination of chronic infection a real possibility ahead of the WHO 2030 target. However, the extent of unidentified cases remains a problem, and will also apply when new curative drugs for hepatitis B virus become available. We also describe efforts to improve standards of hospital care for liver disease with better understanding of current service deficiencies and a new accreditation process for hospitals providing liver services. New commissioning arrangements for primary and community care represent progress, in terms of effective screening of high-risk subjects and the early detection of liver disease.
BASE
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
In: Marshall , A D , Cunningham , E B , Nielsen , S , Aghemo , A , Alho , H , Backmund , M , Bruggmann , P , Dalgard , O , Seguin-Devaux , C , Flisiak , R , Foster , G R , Gheorghe , L , Goldberg , D , Goulis , I , Hickman , M , Hoffmann , P , Jancoriene , L , Jarcuska , P , Kåberg , M , Kostrikis , L G , Makara , M , Maimets , M , Marinho , R T , Maticic , M , Norris , S , Ólafsson , S , Øvrehus , A , Pawlotsky , J-M , Pocock , J , Robaeys , G , Roncero , C , Simonova , M , Sperl , J , Tait , M , Tolmane , I , Tomaselli , S , van der Valk , M , Vince , A , Dore , G J , Lazarus , J V & Grebely , J 2018 , ' Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe ' , The Lancet Gastroenterology & Hepatology , vol. 3 , no. 2 , pp. 125–133 . https://doi.org/10.1016/S2468-1253(17)30284-4
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.
BASE
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
In: Marshall , A D , Cunningham , E B , Nielsen , S , Aghemo , A , Alho , H , Backmund , M , Bruggmann , P , Dalgard , O , Seguin-Devaux , C , Flisiak , R , Foster , G R , Gheorghe , L , Goldberg , D , Goulis , I , Hickman , M , Hoffmann , P , Jancorienė , L , Jarcuska , P , Kåberg , M , Kostrikis , L G , Makara , M , Maimets , M , Marinho , R T , Matičič , M , Norris , S , Ólafsson , S , Øvrehus , A , Pawlotsky , J-M , Pocock , J , Robaeys , G , Roncero , C , Simonova , M , Sperl , J , Tait , M , Tolmane , I , Tomaselli , S , van der Valk , M , Vince , A , Dore , G J , Lazarus , J V , Grebely , J 2018 , ' Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe ' , Lancet Gastroenterology and Hepatology , vol. 3 , no. 2 , pp. 125–133 . https://doi.org/10.1016/S2468-1253(17)30284-4
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.
BASE
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
In: Marshall , A D , Cunningham , E B , Nielsen , S , Aghemo , A , Alho , H , Backmund , M , Bruggmann , P , Dalgard , O , Seguin-Devaux , C , Flisiak , R , Foster , G R , Gheorghe , L , Goldberg , D , Goulis , I , Hickman , M , Hoffmann , P , Jancorienė , L , Jarcuska , P , Kåberg , M , Kostrikis , L G , Makara , M , Maimets , M , Marinho , R T , Matičič , M , Norris , S , Ólafsson , S , Øvrehus , A , Pawlotsky , J-M , Pocock , J , Robaeys , G , Roncero , C , Simonova , M , Sperl , J , Tait , M , Tolmane , I , Tomaselli , S , van der Valk , M , Vince , A , Dore , G J , Lazarus , J V , Grebely , J & International Network on Hepatitis in Substance Users (INHSU) 2018 , ' Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe ' , The Lancet Gastroenterology & Hepatology , vol. 3 , no. 2 , pp. 125-133 . https://doi.org/10.1016/S2468-1253(17)30284-4
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.
BASE